Cyrano Therapeutics is developing CYR-064, an intranasal pharmaceutical therapy aimed at restoring olfactory function in patients experiencing chronic loss of smell and taste, particularly due to viral infections. This condition affects millions, significantly impacting quality of life, and the company is conducting a 32-week clinical trial to evaluate the safety and effectiveness of its treatment.
Funding
$9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DCFounders
Product
Problem
Millions of individuals experience chronic loss of smell and taste, often triggered by viral infections, significantly diminishing their quality of life and overall well-being. This condition can impair the ability to enjoy food, detect hazards, and engage in social interactions.
Solution
Cyrano Therapeutics is developing CYR-064, an intranasal pharmaceutical therapy designed to restore olfactory function in patients suffering from long-term smell and taste loss. The therapy aims to address the underlying causes of hyposmia, the partial loss of smell, and anosmia, the complete loss of smell. By delivering targeted treatment directly to the olfactory system, CYR-064 seeks to regenerate damaged olfactory receptors and neural pathways, thereby improving the patient's ability to perceive and differentiate odors. The company is currently conducting a clinical trial to evaluate the safety and efficacy of CYR-064 in restoring olfactory function.
Target Audience
The primary target audience includes individuals experiencing chronic smell and taste loss due to viral infections, head trauma, or neurodegenerative diseases, as well as physicians specializing in otolaryngology and neurology.
Features
- Intranasal administration for direct targeting of the olfactory epithelium
- Pharmaceutical formulation designed to promote regeneration of olfactory neurons
- Clinical trial underway to assess safety and efficacy in patients with post-viral olfactory dysfunction
- Double-blinded, placebo-controlled study design to ensure rigorous evaluation of treatment effects
- 32-week trial duration to assess long-term effects on olfactory function